|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,470.50 GBX | +0.19% |
|
+1.70% | -31.39% |
| Nov. 19 | SkinBioTherapeutics Finalizes SkinBiotix Commercialization Deal with Croda | MT |
| Nov. 19 | Croda International plc Announces Directorate Change | CI |
| Capitalization | 4.84B 6.18B 5.84B 5.42B 8.73B 525B 9.57B 67.4B 24.88B 215B 23.22B 22.71B 934B | P/E ratio 2024 * |
28.5x | P/E ratio 2025 * | 23.9x |
|---|---|---|---|---|---|
| Enterprise value | 5.33B 6.82B 6.44B 5.98B 9.63B 578B 10.55B 74.31B 27.43B 237B 25.6B 25.04B 1,030B | EV / Sales 2024 * |
3.26x | EV / Sales 2025 * | 3.1x |
| Free-Float |
-
| Yield 2024 * |
3.19% | Yield 2025 * | 3.3% |
More valuation ratios
* Estimated data
More news
Last Transcript: Croda International Plc
More recommendations
More press releases
More news
| 1 day | -0.85% | ||
| 1 week | +1.58% | ||
| Current month | +0.41% | ||
| 1 month | -3.88% | ||
| 3 months | -12.79% | ||
| 6 months | -19.80% | ||
| Current year | -31.41% |
1 week
3 359.35
3 472.00
1 month
3 359.353 821.00
Current year
3 359.355 124.00
1 year
3 359.355 154.00
3 years
3 359.3510 505.00
5 years
3 359.3510 505.00
10 years
2 648.2010 505.00
| Director | Title | Age | Since |
|---|---|---|---|
Stephen Foots
CEO | Chief Executive Officer | 55 | 2011-12-30 |
| Director of Finance/CFO | 56 | 2024-06-30 | |
Mark Robinson
COO | Chief Operating Officer | - | 2020-08-31 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stephen Foots
BRD | Director/Board Member | 55 | 2010-06-30 |
Keith Layden
BRD | Director/Board Member | 64 | 2011-12-31 |
Tom M. Brophy
BRD | Director/Board Member | 50 | 2012-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.55% | 20 M€ | +16.38% | - | |
| 0.48% | 55 M€ | +3.50% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -0.85% | +1.58% | -27.33% | -66.40% | 6.18B | ||
| -0.38% | +0.38% | +29.81% | +8.27% | 70.62B | ||
| -0.36% | +1.38% | -4.15% | -37.37% | 43.09B | ||
| +0.29% | -0.03% | +15.04% | -18.61% | 41.06B | ||
| +0.06% | -1.99% | +16.34% | +18.18% | 27.03B | ||
| -0.12% | +0.72% | -3.44% | -31.93% | 16.86B | ||
| +0.37% | -2.58% | -3.27% | -21.13% | 15.07B | ||
| +4.48% | -1.47% | -14.32% | -57.41% | 12.89B | ||
| +1.35% | +0.43% | +22.12% | +45.47% | 11.34B | ||
| +6.07% | +1.33% | -21.50% | -29.62% | 11.53B | ||
| Average | +1.10% | -0.01% | +0.93% | -19.05% | 25.57B | |
| Weighted average by Cap. | +0.45% | +0.16% | +9.89% | -12.25% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 1.63B 2.09B 1.98B 1.83B 2.95B 177B 3.23B 22.79B 8.41B 72.79B 7.85B 7.68B 316B | 1.72B 2.2B 2.08B 1.93B 3.1B 187B 3.4B 23.96B 8.85B 76.53B 8.25B 8.07B 332B |
| Net income | 167M 214M 202M 188M 302M 18.16B 331M 2.33B 861M 7.45B 804M 786M 32.33B | 201M 257M 243M 225M 363M 21.82B 398M 2.8B 1.03B 8.95B 965M 944M 38.83B |
| Net Debt | 495M 634M 599M 556M 895M 53.77B 980M 6.91B 2.55B 22.06B 2.38B 2.33B 95.71B | 496M 634M 600M 556M 896M 53.83B 982M 6.92B 2.55B 22.09B 2.38B 2.33B 95.82B |
More financial data
* Estimated data
Employees
5,852
Sector
Specialty Chemicals
Calendar
2025-02-25
- Q4 2024 Earnings Release
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-12-10 | 3,465.00 p | +0.03% | 39,476 |
| 24-12-09 | 3,464.00 p | +1.61% | 448,472 |
| 24-12-06 | 3,409.00 p | +1.19% | 3,425,241 |
| 24-12-05 | 3,369.00 p | -1.43% | 1,053,968 |
| 24-12-04 | 3,418.00 p | +0.32% | 833,696 |
Delayed Quote London S.E., December 09, 2024 at 11:35 am EST
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
34.64GBP
Average target price
45.36GBP
Spread / Average Target
+30.95%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CRDA Stock